A bill to amend the American Taxpayer Relief Act of 2012 to delay implementation of the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system.

Bill 118 s 4510, also known as the "Delay of Inclusion of Oral-Only ESRD-Related Drugs in Medicare ESRD Prospective Payment System Act," aims to amend the American Taxpayer Relief Act of 2012. The bill seeks to delay the implementation of including oral-only drugs related to End-Stage Renal Disease (ESRD) in the Medicare ESRD prospective payment system.

The bill recognizes the importance of ensuring that individuals with ESRD have access to necessary medications, including oral-only drugs. By delaying the inclusion of these drugs in the Medicare ESRD prospective payment system, the bill aims to provide more time for stakeholders to assess the impact of this change and make any necessary adjustments.

This legislation is crucial in ensuring that individuals with ESRD continue to receive the medications they need to manage their condition effectively. By delaying the implementation of this policy change, the bill allows for a more thoughtful and comprehensive approach to be taken in addressing the inclusion of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system. Overall, Bill 118 s 4510 serves to protect the interests of individuals with ESRD and ensure that they continue to receive the necessary care and medications they need to maintain their health and well-being.